What Does the Evidence Say About Ozempic and Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Targeted Pharmacovigilance

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may wonder whether the medication could be causing gastroparesis. Medical literature has long emphasized the importance of monitoring drug safety across diverse patient populations. This page reviews the current evidence examining a potential causal link between Ozempic and gastroparesis. This topic is part of an established body of medical research and pharmacovigilance.

Understanding Gastroparesis and Ozempic’s Mechanism

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, symptom assessment, and exclusion of other causes. The condition can significantly impair quality of life and nutritional status. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for cardiovascular risk reduction. Its pharmacology includes slowing of gastric emptying, which is a known mechanism contributing to its glucose-lowering effects. This pharmacodynamic action raises mechanistic plausibility for a link between Ozempic and gastroparesis, as delayed gastric emptying is the hallmark of the disorder. Evidence from clinical trials demonstrates that gastrointestinal adverse reactions are common with Ozempic. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects.

Clinical Evidence and Reported Symptoms

Specific gastrointestinal adverse reactions reported with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these terms are not synonymous with gastroparesis, they reflect upper gastrointestinal dysfunction that can overlap with gastroparesis symptoms. The label does not explicitly list gastroparesis as an adverse reaction, but the mechanistic slowing of gastric emptying and the pattern of reported symptoms suggest a potential continuum. Regarding risk considerations, the adequacy of warnings for Ozempic and gastroparesis is a key concern. The prescribing information includes warnings for serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not contain a specific warning for gastroparesis. This absence may leave patients and clinicians unaware of the potential for severe or persistent delayed gastric emptying beyond typical transient gastrointestinal effects.

Causation Considerations and Clinical Implications

For affected patients, causation considerations involve the temporal relationship between Ozempic initiation and symptom onset. The label notes that gastrointestinal reactions predominantly occur during dose escalation, but some patients may develop chronic symptoms that persist or worsen over time. The timeline between exposure and documented harm can vary; acute symptoms may appear within weeks of starting therapy or after dose increases, while chronic gastroparesis may develop insidiously. Discontinuation of Ozempic often leads to symptom improvement, but recovery may be incomplete in some cases. In summary, the evidence supports a plausible mechanistic link between Ozempic and gastroparesis through its known effect on gastric emptying. Clinical trial data show a high incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis, though the label does not explicitly warn of this condition. Patients and healthcare providers should be vigilant for signs of gastroparesis, especially during dose escalation, and consider discontinuation if symptoms are severe or persistent. Further research is needed to clarify the incidence, risk factors, and long-term outcomes of Ozempic-associated gastroparesis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Ozempic could cause gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its glucose-lowering effect. This pharmacodynamic action is the same mechanism underlying gastroparesis, a condition of delayed gastric emptying. Clinical trial data show dose-dependent increases in gastrointestinal adverse reactions, including symptoms like nausea, vomiting, and dyspepsia, which overlap with gastroparesis symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label include a warning about gastroparesis?

No, the prescribing information for Ozempic does not explicitly list gastroparesis as an adverse reaction. It includes warnings for serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but not for gastroparesis. This absence may leave patients and clinicians unaware of the potential for severe or persistent delayed gastric emptying.

What should I do if I experience symptoms of gastroparesis while taking Ozempic?

If you experience persistent nausea, vomiting, early satiety, bloating, or abdominal pain while on Ozempic, consult your healthcare provider. Symptoms may be more common during dose escalation. Your doctor may consider discontinuing Ozempic or adjusting the dose. In many cases, symptoms improve after stopping the medication, but recovery may be incomplete.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.